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A new strategy for rapidly selecting and testing genetic vaccines has been developed, in which a whole genome
library is cloned into a bacteriophage  ZAP Express vector which contains both prokaryotic (Plac) and
eukaryotic (PCMV) promoters upstream of the insertion site. The phage library is plated on Escherichia coli
cells, immunoblotted, and probed with hyperimmune and/or convalescent-phase antiserum to rapidly identify
vaccine candidates. These are then plaque purified and grown as liquid lysates, and whole bacteriophage
particles are then used directly to immunize the host, following which PCMV-driven expression of the candidate
vaccine gene occurs. In the example given here, a semirandom genome library of the bovine pathogen
Mycoplasma mycoides subsp. mycoides small colony (SC) biotype was cloned into  ZAP Express, and two
strongly immunodominant clones, -A8 and -B1, were identified and subsequently tested for vaccine potential
against M. mycoides subsp. mycoides SC biotype-induced mycoplasmemia. Sequencing and immunoblotting
indicated that clone -A8 expressed an isopropyl--D-thiogalactopyranoside (IPTG)-inducible M. mycoides
subsp. mycoides SC biotype protein with a 28-kDa apparent molecular mass, identified as a previously
uncharacterized putative lipoprotein (MSC_0397). Clone -B1 contained several full-length genes from theM.
mycoides subsp. mycoides SC biotype pyruvate dehydrogenase region, and two IPTG-independent polypeptides,
of 29 kDa and 57 kDa, were identified on immunoblots. Following vaccination, significant anti-M. mycoides
subsp. mycoides SC biotype responses were observed in mice vaccinated with clones -A8 and -B1. A
significant stimulation index was observed following incubation of splenocytes from mice vaccinated with clone
-A8 with whole live M. mycoides subsp. mycoides SC biotype cells, indicating cellular proliferation. After
challenge, mice vaccinated with clone -A8 also exhibited a reduced level of mycoplasmemia compared to
controls, suggesting that the MSC_0397 lipoprotein has a protective effect in the mouse model when delivered
as a bacteriophage DNA vaccine. Bacteriophage-mediated immunoscreening using an appropriate vector
system offers a rapid and simple technique for the identification and immediate testing of putative candidate
vaccines from a variety of pathogens.
Whole bacteriophage (phage)  particles have recently been
described as highly efficient DNA vaccine delivery vehicles (6,
7, 17, 20), inducing significant antibody responses in both lab-
oratory mice (7) and larger animals such as rabbits (20) and
sheep (33). Bacteriophages are viruses of bacteria and are
metabolically inert, requiring the host bacterium for growth
and propagation. Using standard “naked” DNA vaccination,
purified genetic material in the form of a plasmid encoding
protective antigens is given to the host and used to stimulate an
immune response and give protection against pathogens (37,
42). With bacteriophage genetic immunization, expression cas-
settes containing a vaccine gene under the control of a suitable
eukaryotic promoter (e.g., the cytomegalovirus [CMV] pro-
moter) are simply cloned into a standard  DNA cloning vec-
tor. The DNA is subsequently packaged in vitro, and the vac-
cine phage is then easily propagated on an Escherichia coli
host. When whole recombinant bacteriophage particles con-
taining DNA vaccines are injected into a host (phage vaccina-
tion), the protein coat of the bacteriophage protects the DNA
from degradation. Being particulate antigens, bacteriophage
are taken up by antigen-presenting cells (APCs) (3), cleared
from the circulation, and targeted to the spleen and liver Kup-
pfer cells (9, 12, 14). Thus, phages represent an extremely
simple and effective technology for targeting DNA vaccines to
APCs. Bacteriophage vaccines are cheap, stable (13), and easy
to produce, permit the cloning of relatively large inserts (up to
20 kb for lambda vectors), do not require the presence of
antibiotic resistance genes, and are unable to replicate in eu-
karyotic cells. Vaccination with phage particles also induces a
highly immunogenic signal (against phage coat proteins),
which provides an easily assayable marker to confirm the vac-
cination status of animals. Previous research has indicated that
high phage antibody titers do not interfere with the immune
response against the expressed DNA vaccine antigen, and if
anything, are more likely to efficiently target the phage to
APCs (via phage-antibody complexes [20]).
As a research tool, phage  vectors are ideal for constructing
genomic expression libraries. In a vector such as  ZAP Ex-
press (Stratagene), the DNA insert is under the transcriptional
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control of both an inducible prokaryotic promoter (Plac, induc-
ible with isopropyl--D-1-thiogalactopyranoside [IPTG]) and
the strong constitutive cytomegalovirus promoter (PCMV) to
drive eukaryotic transcription. Once a suitable library has been
constructed, whole-library genetic immunization can be car-
ried out without any further manipulation (17). Alternatively,
the same library can be rapidly screened by plating phage on E.
coli in the presence of IPTG and immunoblotting with conva-
lescent-phase or hyperimmune sera to identify immunodomi-
nant clones. These potential vaccine candidates can then be
isolated, the insert DNA rapidly sequenced, and whole phage
particles produced and immediately screened in vivo for pro-
tective efficacy, either singly or as a mixture, without the need
for further manipulation. If required, the recombinant proteins
can also be expressed and purified directly from E. coli by
excising the integral pBK-CMV phagemid vector by using a
helper phage. We have already performed preliminary immu-
nogenicity testing in mice of a whole bacteriophage  semir-
andom genomic library of Mycoplasma mycoides subsp. my-
coides small colony (SC) biotype (5), the causal agent of
contagious bovine pleuropneumonia (CBPP). This is an eco-
nomically important disease of cattle currently affecting much
of Africa and, until recently, southern Europe for which cur-
rent live attenuated vaccines offer poor efficacy (for a recent
review, see reference 27). The aforementioned M. mycoides
subsp. mycoides SC biotype phage vaccine study has now been
extended by picking two clones from the library expressing
immunodominant proteins which have been tested as whole
phage  vaccines for their immunogenicity and protective ef-
ficacy against M. mycoides subsp. mycoides SC biotype-induced
mycoplasmemia, using a mouse infection technique (36).
MATERIALS AND METHODS
Mycoplasma strains and growth conditions. M. mycoides subsp. mycoides SC
biotype challenge strain N6 (19) was grown in HEPES-Gourlay’s broth or agar
(1%) medium (38) at 37°C in an atmosphere containing 5% CO2. For the
challenge experiment, the mycoplasma culture was grown to mid-logarithmic
phase, concentrated 10-fold by centrifugation, and resuspended in fresh medium
immediately before challenge to give a titer of 5  1010 organisms/ml.
Antisera. Rabbit hyperimmune serum (R55) was raised against M. mycoides
subsp. mycoides SC biotype strain N6 and has already been described (19). The
immunoglobulin G (IgG) fraction was purified using a protein A column (Roche
Diagnostics Ltd.) following the manufacturer’s recommended protocol and stored at
10 mg/ml. CBBP-specific convalescent-phase antiserum was obtained from naturally
infected cattle from field outbreaks in Tanzania and was provided by Benedict Lema,
Animal Diseases Research Institute, Dar-es-Salaam, Tanzania.
Preparation of bacteriophage  M. mycoides subsp. mycoides SC biotype
genomic library. DNA was prepared from M. mycoides subsp. mycoides SC
biotype vaccine strain T144 by previously described methods (19) and partially
digested with Tsp509I (New England Biolabs), which has the recognition se-
quence AATT. The DNA was size fractionated in an agarose gel, and fragments
in the range of 6 to 8 kb were excised, purified, and then cloned into the unique
EcoRI site of the expression vector  ZAP Express (Stratagene), in which inserts
are under the control of both a prokaryotic (lacZ) and a eukaryotic (CMV)
promoter. The resulting library was amplified and plated on E. coli strain XL1-
Blue (Stratagene) in the presence of IPTG to induce prokaryotic expression. The
plaques were then blotted onto nitrocellulose membranes and incubated with
purified rabbit anti-M. mycoides subsp. mycoides SC biotype IgG (R55), and
standard immunoscreening protocols were used to identify M. mycoides subsp.
mycoides SC biotype-expressing clones (approximately one-third of clones gave a
signal, with various degrees of intensity). The most strongly positive clones were
picked, replated on E. coli, and screened with CBPP-specific convalescent-phase
sera from three different cattle (preadsorbed with E. coli cells lysed with a  ZAP
Express vector without any insert to reduce the nonspecific background). The 
clones which gave a strong (immunodominant) signal with all three bovine
convalescent-phase sera were selected for further study. Phagemids were excised
from these clones directly into E. coli strain XLOLR (Stratagene), using the
recommended protocol ( ZAP Express instruction manual, Stratagene). Insert
protein expression was examined by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and immunoblotting with R55 IgG, while the in-
sert DNA was sequenced using the phagemid T7 and T3 sequencing primers
adjacent to the insert multicloning site on a PE Biosystems 377 DNA sequencer.
Open reading frames for both E. coli and mycoplasma codon usage were deter-
mined using the ORF-finder web-based sequence analysis tool at the NCBI
website (www.ncbi.nlm.nih.gov/gorf/gorf.html), while sequences were aligned to
the published M. mycoides subsp. mycoides SC biotype strain PG1 sequence (40)
by using BLAST searches.
Immunoblots. E. coli strain XLOLR cells containing phagemids of interest
were grown in 10 ml LB-kanamycin broth to an optical density at 600 nm of 0.4
to 1.0. IPTG (0.2 mM) was then added, and incubation was continued for a
further 3 to 4 h. Cells were pelleted and resuspended in a small volume (100 to
400 l, depending on the cell density) of SDS-PAGE sample buffer (0.1 M
Tris-HCl, pH 6.8, 40% [vol/vol] glycerol, 4% [wt/vol] SDS, 0.25% bromophenol
blue, 2% -mercaptoethanol). The samples were boiled for 5 min, separated by
SDS-PAGE, and immunoblotted using standard procedures as previously de-
scribed (20). Blots were probed using rabbit (R55) or mouse primary antiserum
and a relevant secondary antiserum (DAKO A/S, Glostrup, Denmark).
Growth and purification of bacteriophage  for vaccine preparation. The
negative control phage -gt11, which does not contain any M. mycoides subsp.
mycoides SC biotype DNA, was produced on E. coli strain LE392 (26), while 
ZAP Express M. mycoides subsp. mycoides SC biotype clones were grown on
strain XL1-Blue (Stratagene). Large-scale liquid lysates of phage  were pre-
pared, purified using previously published protocols (essentially polyethylene
glycol precipitation followed by ultracentrifugation) (20), and stored at 4°C
until use.
Mouse challenge experiment. The mice used were female BALB/c mice of 10
weeks of age, with eight mice used per group. Three mouse groups were tested.
Group 1 mice were immunized with  ZAP Express clone A8, group 2 mice were
immunized with clone B1, and group 3 mice were negative control mice and were
injected with gt-11. All mice were injected intramuscularly on weeks 0, 4, and
11 with 50 l SM saline buffer containing 5  109 bacteriophage particles. Mice
were bled from the tail prevaccination at week 0, postvaccination at weeks 4, 8,
and 13 (immediately prior to challenge at week 13), and postchallenge at 43, 68,
and 92 h.
At week 13, all three groups of BALB/c mice were challenged by intraperito-
neal injection of 0.5 ml (2.5 1010 organisms) of M. mycoides subsp. mycoides SC
biotype strain N6. Previous research had indicated that this strain produced a
particularly high degree of mycoplasmemia in mice (18). All mice were held in
negative-pressure isolators (one group per isolator) to satisfy current disease
security requirements. A drop of blood from tail-tip bleeds was placed in 3 ml of
liquid growth medium before being diluted 101 and 102 in the same medium
and incubated at 37°C for 7 days. Growth in liquid medium (observed as a color
change from red to yellow of 1-in-10 dilutions) was confirmed with an M.
mycoides subsp. mycoides SC biotype-specific latex agglutination test (21) and by
plating on solid medium and observing mycoplasma colonies. Finally, all mice
were humanely killed and bled at 92 h postchallenge, and spleens were obtained
for stimulation assays.
ELISA analysis of sera. Antibody titers against bacteriophage  coat proteins
and whole M. mycoides subsp. mycoides SC biotype antigens (strain T144) were
measured by an indirect enzyme-linked immunosorbent assay (ELISA) following
previously published procedures (20). Microtiter plates (96-well; Greiner Ltd.,
Brunel Way, Stonehouse, Gloucestershire, United Kingdom) were coated over-
night at 4°C with 0.05 M sodium carbonate buffer at pH 9.2 and either whole
sonicated M. mycoides subsp. mycoides SC biotype (N6) at a concentration of 5
g/ml or 109 gt-11 bacteriophage (50 ng) per well.
Lymphocyte stimulation assay (LSA). Spleens were harvested from each
mouse at 96 h postchallenge and combined for each of the three groups (eight
spleens per group). Splenocytes were recovered from the spleens via injection
with 2 ml mouse wash medium (Hanks balanced salt solution, 2% fetal bovine
serum, 2% penicillin-streptomycin, 0.25% nystatin, and 0.2% gentamicin [Lloyds
Chemist PLC, United Kingdom]) and rubbing between sterile microscope slides.
This cell suspension was then filtered through lens tissue (Whatman Interna-
tional Ltd., England) before being centrifuged for 5 min at 1,500 rpm at 16°C.
The pellet was resuspended in lysis buffer (9 parts 0.16 M ammonium chloride
[Sigma] and 1 part 0.17 M Tris-HCl [Sigma] at pH 7.65). After 10 min at 4°C,
lysis was stopped by the addition of mouse wash medium. Following centrifuga-
tion at 1,500 rpm for 5 min at 16°C, the pellet was resuspended in complete
RPMI (RPMI 1640, 10% fetal bovine serum, 2% glutamine, 1% penicillin-
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streptomycin, 1% gentamicin, 0.5% 2-mercaptoethanol, 2.5% sodium bicarbon-
ate, and 1.2% 1 M HEPES [Sigma]). This cell suspension was centrifuged again
(as described above), and the pellet was resuspended in 1 ml complete RPMI. A
1:10 dilution of cell suspension in 0.1% nigrosin (Sigma) in phosphate-buffered
saline was prepared for a viability count using a modified Neubauer counting
chamber. The cell concentration was adjusted to 1  106 cells/ml in complete
RPMI. Using sterile 96-well tissue culture plates, 100 l (105) of viable spleno-
cytes was seeded into 100-l aliquots of sterile diluted antigens containing 106
live M. mycoides subsp. mycoides SC biotype cells or 5 or 2.5 g/ml gt-11
particles. All assays were performed in triplicate, with average values and stan-
dard deviations being calculated. Samples were taken daily and cultured for
mycoplasma growth (none could be detected; M. mycoides subsp. mycoides SC
biotype strain N6 is streptomycin sensitive [data not shown]). As a positive
control, cells were cultured with concanavalin A (Sigma), which was present at a
final concentration of 2.5 g/ml. Plates were incubated in a humid 5% CO2
environment at 37°C for 96 h and then pulsed for 18 h with 18.25 kBq (1Ci)
[3H]thymidine (Amersham Biosciences, United Kingdom) per well. The cells
were harvested with a Packard Harvester onto glass fiber filters (Packard, The
Netherlands), and activity was counted in a direct beta counter (Packard). Re-
sults were expressed as average counts per minute (cpm)  standard deviations,
from which stimulation indices (SI) were calculated using the following equation:
SI  average cpm of test/average cpm of control medium without antigenic
stimulus.
Statistical analysis. Comparisons of group ELISA titers were analyzed using
Student’s two-tailed t test. The mean values of triplicate ELISA titers for serum
samples were compared between groups (n  8 samples per group). For lym-
phocyte stimulation assays, pooled mouse spleens from each group were assayed
in triplicate, and values between groups were compared using a two-tailed t test.
For the challenge experiment, Fisher’s exact probability test was used to compare
the numbers of mycoplasmemic mice in different groups.
RESULTS
Isolation and expression profiles of -A8 and -B1 clones.
Following immunoscreening of the M. mycoides subsp. my-
coides SC biotype  ZAP Express library (containing ca. 106
primary clones), the most strongly positive clones were grown
up, recombinant phagemids were excised, and the M. mycoides
subsp. mycoides SC biotype genomic inserts were sequenced.
All inserts were given a specific letter and number for identi-
fication (e.g., A8). When this insert was contained within a
bacteriophage  vector, it was known as -A8, and when it was
contained within the excised phagemid vector, it was known as
p-A8. The expression profiles of the M. mycoides subsp. my-
coides SC biotype proteins encoded by these clones were ex-
amined by immunoblotting of whole E. coli extracts containing
the individual phagemids grown in the presence (Fig. 1a) or
absence (Fig. 1b) of IPTG, using rabbit hyperimmune M. my-
coides subsp. mycoides SC biotype-specific antiserum. Not all
phagemid clones were positive following immunoblotting com-
pared to plaque lifts (e.g., clones B2, B6, and C9) due to
extremely poor growth of cells harboring these cloned inserts
as plasmids.
Only clone p-A8 appeared to express an IPTG-inducible M.
mycoides subsp. mycoides SC biotype protein (28 kDa), indi-
cating expression originating from the Plac promoter of the
phagemid vector. For most of the clones, similar expression
profiles were observed in the presence and absence of IPTG,
suggesting that most M. mycoides subsp. mycoides SC biotype
protein expression was being internally primed. Since M. my-
coides subsp. mycoides SC biotype DNA is highly AT rich
(75%) (40), this was not unexpected, with aberrant transcrip-
tion initiation often occurring with mycoplasma DNA when
maintained within an E. coli host (25). However, it makes
specific identification of the expressed M. mycoides subsp. my-
coides SC biotype proteins more difficult since it is not obvious
where the transcriptional start site lies within the insert. The
identification of expressed proteins is further hampered by the
fact that in mycoplasmas the typical UGA stop codon encodes
a tryptophan. In most expression systems, mycoplasma pro-
teins containing UGA are expressed as truncated proteins un-
less suppressor strains are used.
Based on the published M. mycoides subsp. mycoides SC
biotype strain PG1 DNA sequence (40) and our own sequence
analysis, it appears likely that the 28-kDa protein (P28) ob-
served in clone A8 (from M. mycoides subsp. mycoides SC
biotype strain T144) represents the PG1 lpp MSC_0397 gene
product (714 bp encoding a prolipoprotein of 237 amino acids
[25.6 kDa]). In a comparison of both DNA sequences, only a
single change was observed (a T-A substitution at position 439,
resulting in a change of leucine to isoleucine from strain PG1
to T144). This protein has the same predicted size using both
mycoplasma and E. coli codon usage, since the lpp gene
contains no UGA codons and the start of the open reading
FIG. 1. Immunoblots of E. coli whole-cell extracts containing excised M. mycoides subsp. mycoides SC biotype genomic phagemids grown in
either the presence (a) or absence (b) of IPTG, using rabbit hyperimmune M. mycoides subsp. mycoides SC biotype antiserum.
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frame (ORF) is located immediately downstream of the Plac
promoter.
Clones p-A1, p-A3, p-B1, and p-B21 all exhibited identical
expression profiles, with M. mycoides subsp. mycoides SC bio-
type proteins seen at 29 kDa (P29) and 57 kDa (P57), although
with clone p-A3 P57 was expressed at a greatly reduced level
compared to P29 (Fig. 1). When the inserts were sequenced,
each clone was found to contain a differently sized insert (clone
B21, 6.8 kb; clone A1, 5.8 kb; clone B1, 6.7 kb; clone A3, 5.6
kb). However, there was a region of approximately 3.7 kb
which was common to all four clones (Fig. 2) and which pre-
sumably contains the coding regions for P29 and P57. Using
the previously annotated PG1 sequence as a guide, only two
mycoplasmal ORFs are wholly contained within the 3.7-kb
overlapping region: they are MSC_0268 (pdhD, encoding the
EIII dihdydrolipoamide dehydrogenase subunit of pyruvate
dehydrogenase [64.3 kDa]) and MSC_0269 (pta, encoding a
phosphate acetyltransferase [35.7 kDa]). It is possible that P57
and P29 represent these two full-length gene products, respec-
tively, with any size discrepancy being due to limitations of
SDS-PAGE, since no UGA codons are present internally in
the correct locations to account for these sizes (data not
shown).
Antibody responses following vaccination of mice with -A8
and -B1. Three groups of mice were vaccinated intramuscu-
larly at weeks 0, 4, and 11 with the following whole phage 
particles: clones -A8 (group 1) and -B1 (group 2) and a
negative control, -gt11 (group 3). Following experimental
challenge at week 13 with M. mycoides subsp. mycoides SC
biotype strain N6, antibody responses (at 92 h postchallenge)
against whole M. mycoides subsp. mycoides SC biotype proteins
in the three vaccinated mouse groups were measured by
ELISA (Fig. 3). Compared to those for the mouse group vac-
cinated with the control phage -gt11, higher antibody titers
against whole mycoplasma proteins were observed for the
groups vaccinated with -A8 (P  0.04) and -B1 (P  0.08),
although the intensities of the responses were relatively low
overall. All mice showed high-level antibody responses against
phage coat proteins when these were used as the ELISA an-
tigen (data not shown).
In order to demonstrate the specificity of these immune
responses, whole-cell extracts of E. coli containing recombi-
nant phagemid p-A8 or p-B1 were separated by SDS-PAGE
and immunoblotted using sera from vaccinated and challenged
mice. Cells were grown in the presence of IPTG to induce M.
mycoides subsp. mycoides SC biotype recombinant protein ex-
pression where necessary. The E. coli p-A8 extract was probed
with sera from group 1 mice 4 and 8 (vaccinated with -A8)
and with a negative control serum (group 3 mouse 4 [vacci-
nated with -gt11]). The results are shown in Fig. 4a. It is clear
that a specific protein band, at approximately 28 kDa, was
detected with the sera from two mice immunized with -A8 but
was not recognized with the serum from a mouse given the
-gt11 negative control phage. This 28-kDa protein is almost
certainly the same IPTG-inducible P28 recognized by rabbit
FIG. 2. Arrangement of ORFs found in the four overlapping  ZAP Express clones covering the pyruvate dehydrogenase (PDH) region of the
genome. The large arrows represent the proteins expressed in mycoplasmas. In total, the four clones cover a region putatively expressing the C
termini of MSC_0265 (pdhA, encoding 259 of 371 amino acids of the EI	 lipoamide dehydrogenase subunit of pyruvate dehydrogenase),
MSC_0266 (pdhB, encoding the EI lipoamide dehydrogenase subunit of pyruvate dehydrogenase), MSC_0267 (pdhC, encoding the EII dihy-
drolipoamide S-acetyltransferase subunit of pyruvate dehydrogenase), MSC_0268 (pdhD, encoding the EIII dihydrolipoamide dehydrogenase
subunit of pyruvate dehydrogenase), MSC_0269 (pta, encoding a phosphate acetyltransferase), and MSC_0270 (ackA, encoding acetate kinase) and
the N terminus of the MSC_0271 orfA product, a prolipoprotein with high (57.4% identity) homology to the putative Mycoplasma capricolum
lipoprotein OrfA (data not shown).
FIG. 3. Individual antibody responses against whole sonicated M.
mycoides subsp. mycoides SC biotype antigen in vaccinated mouse
groups (n  8 mice per group). The standard deviations of individual
mouse values are shown. Overall group responses were compared by a
t test. Group 1 mice were vaccinated with -A8 (P  0.04 compared to
group 3), group 2 mice were vaccinated with -B1 (P  0.08 compared
to controls), and group 3 (negative control) mice were vaccinated with
-gt11. OD, optical density.
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anti-M. mycoides subsp. mycoides SC biotype serum when used
to probe the E. coli p-A8 extract (Fig. 1), indicating that both
prokaryotic and eukaryotic expression of this protein occurs
from the construct (i.e., the expression of P28 must also have
occurred in the mouse vaccinated with -A8 in order to lead to
specific P28 antibodies being produced). Similarly, in Fig. 4b,
the results of probing an immunoblot of E. coli p-B1 antigen
extract with mouse sera are shown. In this case, specific protein
bands at 29 kDa and 57 kDa were seen by using sera from two
group 2 mice (-B1) and were absent with the negative control
serum (group 3 mouse 4), indicating both prokaryotic and
eukaryotic expression of P29 and P57 (even though expression
may be internally primed rather than via the Plac or CMV
promoter of the vector since the expression of these proteins in
E. coli does not appear to be IPTG inducible [Fig. 1a and b]).
LSA. The cellular proliferation of pooled mouse splenocytes
from each mouse group (at 92 h postchallenge) was measured
by the incorporation of [3H]thymidine (cpm) in response to
stimulation from whole M. mycoides subsp. mycoides SC bio-
type or whole bacteriophage -gt11 particles. From these val-
ues, the SI compared to a medium-only value of 1.0 was cal-
culated for each mouse group. The responses against a whole
M. mycoides subsp. mycoides SC biotype antigenic stimulus are
shown in Fig. 5a. In common with the antibody response data
(Fig. 3), greater proliferation (P  0.053) was seen in mice
vaccinated with -A8 (SI 2.5 0.1) than in the control group
given -gt11 (SI  1.6  0.4). In contrast, no simulation was
observed for mice vaccinated with -B1 (SI  0.5  0.7).
In contrast to the low SI values seen with whole M. mycoides
subsp. mycoides SC biotype, very high SI values were observed for
group 1 mice (-A8) with whole phage  particles as the antigenic
stimulus (Fig. 5b). SI values of approximately 300 were observed,
which were comparable to those seen with the positive control
stimulus, concanavalin A, indicating that whole phage  particles
are an extremely effective proliferative agent. Bacteriophages in
general are known to be highly immunogenic (6), and our data
reinforce such findings, although the effect of contaminating bac-
terial lipopolysaccharide should not be discounted. High SI values
against whole phage particles were also observed for mouse
groups 2 and 3 (given phage -B1 and -gt11, respectively), al-
though overall the SI values for splenocytes from group 1 animals
were much larger, irrespective of the stimulus (whole phage par-
ticles or concanavalin A). During the dissection of group 1 mice
following challenge with live M. mycoides subsp. mycoides SC
biotype, it was noted that the spleens were generally very large
compared to those of the -gt11-vaccinated group (approximately
twice the size overall; 2  109 splenocytes total for group 1
compared to 1.1  109 for group 3), in agreement with the LSA
results, which suggested that splenocytes from group 1 animals
were generally in a more activated state than those from group 2
and 3 animals. This could indicate more effective priming against
M. mycoides subsp. mycoides SC biotype by phage -A8 than that
against the other immunogens.
FIG. 4. Immunoblots of E. coli whole-cell extracts containing
phagemid p-A8 (a) or p-B1 (b). Immunoblots were probed with two
separate sera from mice immunized with -A8 (a) or -B1 (b). Specific
M. mycoides subsp. mycoides SC biotype proteins are shown. A nega-
tive control lane (using serum from a mouse immunized with -gt11)
is also shown.
FIG. 5. LSAs using pooled mouse splenocytes (n  8) from mouse groups 1, 2, and 3. Stimulation indexes compared to a medium-only value
of 1 are shown. Standard deviation values are shown for each sample (performed in triplicate). The antigen used was whole M. mycoides subsp.
mycoides SC biotype (a), whole bacteriophage particles, or concanavalin A (b). Borderline significance values were observed between group 1
(-A8) and group 3 (-gt11) mice in panel a (P  0.053 by a t test).
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Challenge experiment. Table 1 shows the results of the chal-
lenge experiment (week 13). All mice were negative for M.
mycoides subsp. mycoides SC biotype immediately prior to
challenge. Group 1 mice, immunized with the -A8 vaccine,
showed a clear trend toward protection, with much reduced
mycoplasmemia over the course of the experimental challenge
(8/8 mice were positive on day 2, with a reduction to 1/8 by day
4) compared to mouse groups 2 and 3 (7/8, with a reduction to
5/8 and 4/8, respectively, by day 4). Due to the small number of
mice in these groups, the difference between groups was not
statistically significant (P  0.12 [comparing groups 1 and 3]
and P  0.28 [comparing groups 2 and 3]), even though the
data suggested that vaccination with -A8 reduced the dura-
tion of observed mycoplasmemia.
DISCUSSION
Whole bacteriophage particles have previously been de-
scribed as a new and advantageous delivery method for DNA
vaccines (6). The methodology has been used here for the
rapid isolation and screening of candidate vaccines against
Mycoplasma mycoides subsp. mycoides SC biotype, the causal
agent of CBPP. A semirandom whole genomic library of M.
mycoides subsp. mycoides SC biotype was cloned into the ex-
pression vector  ZAP Express, in which the insert is under the
transcriptional control of both a prokaryotic (Plac) and a eu-
karyotic (PCMV) promoter. The CMV promoter allows the
immunogenicity and/or protective efficacy of this library to
be directly tested in vivo by simply vaccinating animals with
the whole phage library without any further manipulation, and
we have already demonstrated this whole phage library immu-
nization procedure using a Mycoplasma capricolum subsp. ca-
pripneumoniae  ZAP Express library (17). Obviously, a whole
cDNA expression library can also be tested if required. This
system also allows rapid immunoscreening of the library when
plated on E. coli, using Plac-driven expression to identify pu-
tative vaccine candidates. Initially, rabbit M. mycoides subsp.
mycoides SC biotype-specific hyperimmune antiserum was
used to identify clones capable of expressing M. mycoides
subsp. mycoides SC biotype proteins, followed by bovine con-
valescent-phase antiserum to specifically identify those clones
expressing CBPP-immunodominant antigens (assuming that
immunodominance correlates with protection [the positive sig-
nal observed with bovine convalescent-phase antiserum indi-
cates that these antigens must be expressed by M. mycoides
subsp. mycoides SC biotype during a natural infection]). Fol-
lowing subsequent phagemid excision from the  ZAP Express
vector, inserts were sequenced and protein expression profiles
were determined by immunoblotting of phagemid-expressed
proteins in E. coli extracts. In this instance, two clones were
selected for further study, namely, -A8 (containing a 7.1-kb
insert) and -B1 (containing a 6.7-kb insert). These constructs
were then grown and tested for their protective efficacy as
purified whole phage lysates in mice against an M. mycoides
subsp. mycoides SC biotype mycoplasmemia, with both cell-
mediated and humoral immune responses being studied and
compared to those observed in mice given a nonexpressing
-gt11 control bacteriophage.
Phagemid p-A8 appeared to express a major protein band
recognized by M. mycoides subsp. mycoides SC biotype anti-
serum on an immunoblot at approximately 28 kDa (P28), with
a slightly smaller band (26 kDa) of much lower intensity also
present (Fig. 1a). Since these proteins are IPTG inducible,
their expression must be controlled from the Plac promoter of
the vector. From an analysis of the DNA sequence of the A8
insert (data not shown) and the published M. mycoides subsp.
mycoides SC biotype genomic sequence (40), it appears that
the entire open reading frame of lpp MSC_0397 (encoding a
previously uncharacterized prolipoprotein with an unproc-
essed molecular mass of 25.6 kDa) is present, with the ATG
start codon about 50 bp into the cloned fragment. This gene
does not encode any tryptophan residues (encoded by UGA
codons in M. mycoides subsp. mycoides SC biotype), meaning
that the protein should be translated in its entirety in nonmyco-
plasma hosts. In addition to this full-length protein, a transla-
tional fusion comprising 34 amino acids of the vector -galac-
tosidase 	 protein fragment, 16 amino acids from noncoding
M. mycoides subsp. mycoides SC biotype DNA, and the entire
lpp-encoded protein should also be generated, which would
create a larger fusion protein of about 31 kDa. The most likely
explanation is that P28 seen on the immunoblot represents the
latter fusion protein, with translation initiating at the -galac-
tosidase ATG, while the smaller and less intense band (P26)
represents the pure M. mycoides subsp. mycoides SC biotype
lpp-encoded protein sequence. Alternatively, it is also possible
that posttranslational modification may also occur (e.g., cleav-
age of a signal peptide), with P28 representing full-length Lpp
and P26 representing a processed version.
Lpp MSC_0397 is an extremely basic protein, with an ex-
pected pI of 9.58. A preliminary analysis (data not shown) of
the predicted structure of this protein revealed two transmem-
brane helices, one at the N terminus (amino acids 4 to 24) and
one at the C terminus (amino acids 208 to 230). However, the
N-terminal helix has a significant level of homology with the
N-terminal signal sequences of the variable surface protein
Vmm (30) and LppC (31) of M. mycoides subsp. mycoides SC
biotype. A sequence comparison with the published genome
sequence of M. mycoides subsp. mycoides SC biotype also re-
veals N-terminal homology with several other putative lipopro-
teins of M. mycoides subsp. mycoides SC biotype (40). The Lpp
protein has a predicted VVA-C signal peptidase II cleavage
site at amino acids 21 to 24. This strongly suggests that mature
Lpp is a surface-exposed lipoprotein which is modified with
lipid at the cysteine at residue 24 after cleavage of the 23-
amino-acid signal peptide. We are currently attempting to de-
termine the exact function of the lpp gene product.
Four separate overlapping clones were also isolated which
contained a common region of 3.7 kb of M. mycoides subsp.
TABLE 1. Number of mice in each vaccinated group exhibiting
mycoplasmemia after intraperitoneal challenge
Mouse
group Vaccine
No. of mice in a group of 8 showing
mycoplasmemia on the stated day
after challenge
Day 2 Day 3 Day 4
1 -A8 8 5 1
2 -B1 7 7 5
3 -gt11 7 6 4
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mycoides SC biotype DNA (Fig. 2) encoding the pyruvate de-
hydrogenase (Pdh) complex (pdhB, pdhC, and pdhD). Two
full-length ORFs were present in this common 3.7-kb region,
namely, pdhD, encoding the EIII dihydrolipoamide dehydro-
genase subunit of Pdh (64.3 kDa), and pta, encoding a phos-
phate acetyltransferase (35.7 kDa). On an immunoblot, these
clones expressed two M. mycoides subsp. mycoides SC biotype
proteins (P57 and P29) which may represent the full-length
polypeptides (with size discrepancies due to limitations in the
SDS-PAGE system). Alternatively, they may represent N- or
C-terminally truncated versions of these proteins, although it is
not clear exactly where transcription/translation is occurring
since neither of these proteins is IPTG inducible and therefore
must be internally primed. One possibility is that P57 repre-
sents a dimer of P29. An analysis of Fig. 1 reveals a faint
high-molecular-weight “ladder” above the P57 protein which
could support this theory. However, the expression of P57 is
reduced in clone p-A3 compared to that in the other three
constructs. Uniquely, this clone lacks pdhD upstream DNA
(likely to contain a promoter region), which would agree with
the hypothesis that P57 is derived from the pdhD gene product.
The Pdh complex, particularly the lipoyl-binding domain, is
known to be highly immunogenic in other bacterial species
(e.g., Neisseria meningitidis [1], Mycoplasma capricolum [43],
and Mycoplasma hyopneumoniae [24]). In M. mycoides subsp.
mycoides SC biotype, lipoyl-binding domains are found at the
N termini of both the EII (pdhC) and EIII (pdhD) subunits
(using a conserved domain database search [22] through the
NCBI website). The pfam reference for the biotin-lipoyl bind-
ing domain is pfam00364.11. In Mycoplasma pneumoniae, re-
cent research has identified two fibronectin binding proteins,
one with an observed molecular mass of 30 kDa, which was
subsequently determined to be the EI (pdhB) subunit of the
Pdh complex (8). Several studies have suggested that the Pdh
complex may be membrane bound in M. pneumoniae and form
part of an attachment organelle (16, 32). A membrane-bound
location for the M. mycoides subsp. mycoides SC biotype Pdh
complex would agree with its immunogenic nature, since 4 of
10  clones identified using CBPP convalescent-phase anti-
serum carried genes encoding proteins from this region.
Clones -A8 (containing lpp) and -B1 (containing full-
length pdhC, pdhD, pta, and ackA ORFs) were used to vacci-
nate mice, and humoral and cellular responses were assessed.
Since whole M. mycoides subsp. mycoides SC biotype was used
as the ELISA/LSA antigen rather than the purified recombi-
nant proteins encoded by the  vaccines (e.g., Lpp, PdhD, and
Pta), it is likely that the low signal intensities observed for both
procedures (Fig. 3 and 5a) may be due to the limiting amount
of specific antigen, particularly since it is not known how prev-
alent these proteins are among the general M. mycoides subsp.
mycoides SC biotype antigen mix (assuming that 500 different
polypeptides at equal proportions and a binding capacity of 50
ng per well on an ELISA plate would mean only 0.1 ng of
antigen per well). In support of this, strong specific antibody
responses were observed against recombinant proteins (P28
[Lpp], P29, or P57) following immunoblotting. A higher level
of cellular proliferation was also observed in mice vaccinated
with -A8 than in mice given -gt11 control phage when whole
M. mycoides subsp. mycoides SC biotype was used as the anti-
gen. When the cellular responses of the -A8 group were
measured against whole phage particles, a very high stimula-
tion index of up to 350 was noted, in contrast to the medium-
only control (Fig. 5b), indicating excellent cellular priming by
phage particles (which are known to be highly immunogenic)
(15, 41, 44). Interestingly, following challenge of this mouse
group with whole live M. mycoides subsp. mycoides SC biotype
strain N6 cells, a reduced level of mycoplasmemia was ob-
served compared to those for the other two groups, indicating
a trend toward protection for this group (due to the small
number of mice per group, statistical significance was not
achieved). In addition, spleens from this group were approxi-
mately twice the size of controls, indicating a more activated
state suggestive of more efficient priming by -A8.
Current mycoplasma vaccines are generally either live or
inactivated preparations of whole organisms (10, 23, 29, 34).
There has been little success with subunit vaccines or recom-
binant proteins (35), and this is especially true for CBPP, for
which the only Office International des Epizootes-recom-
mended vaccines are freeze-dried live formulations (strain
T144 or its streptomycin-resistant derivative T1SR). Research
designed to produce “next-generation” vaccines (e.g., immu-
nostimulating complex [ISCOM], capsular polysaccharide con-
jugate, or a whole-cell inactivated vaccine) has proceeded,
although with little apparent success (2, 11, 28, 39). It is pos-
sible that a genetic immunization approach may offer the po-
tential for success in the field of mycoplasmal vaccines, since a
successful plasmid-based whole-library immunization against
Mycoplasma pulmonis was reported previously (4). The ap-
proach utilized here, in which rapid whole-library immuno-
screening is followed by immediate in vivo testing of isolated
clones, may offer great potential in the future. This is especially
so for a disease like CBPP, which predominantly affects the
developing world, where the high stability and ease and cheap-
ness of production of bacteriophage vaccines would be a great
benefit. While results obtained in a mouse model may not
necessarily represent the situation in the target species, they do
demonstrate the validity of the strategy, which may also be
applied to both human and veterinary pathogens for which
potential vaccine candidates have not yet been identified.
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